Question 1

Why are spot tests insufficient for host range?

Accepted Answer

A clear zone can result from high-titre lysis from without, where phage adsorb and damage the envelope without completing a replication cycle. Efficiency of plating, comparing plaque counts on the test strain against the propagation host, shows whether infection is productive. Host range tables built on spot results alone routinely overstate coverage.

Question 2

How should a strain panel be assembled?

Accepted Answer

Laboratory reference strains rarely represent circulating clinical diversity in surface receptors, which is what determines susceptibility. A panel drawn from clinical isolates across sites and time, characterised by sequence type and resistance profile, gives a realistic coverage estimate. Panel composition should be described fully, since coverage percentages are meaningless without it.

Question 3

What should resistance characterisation include?

Accepted Answer

Escape mutants appear readily, so frequency should be measured rather than noted. Sequencing the mutants identifies the receptor change involved, and growth or virulence comparison shows whether resistance carries a cost. Where escape reduces fitness or restores antibiotic sensitivity, that trade-off becomes part of the therapeutic argument.

Question 4

How is a cocktail designed rather than assembled?

Accepted Answer

Components should use distinct receptors, so that a single mutation cannot confer escape from all of them, and each should be characterised individually against the panel before combination. Testing whether phages interfere with one another matters too, since competition for adsorption sites can make a mixture less effective than its best member.

Question 5

Why does endotoxin content matter so much?

Accepted Answer

Phage are propagated on the bacteria they kill, so lysates carry substantial bacterial cell wall material that provokes inflammation independently of any therapeutic effect. Purification by chromatography or density gradient, followed by quantification of residual endotoxin, is expected before animal work and essential for interpreting inflammatory readouts.

Question 6

How does phage pharmacokinetics differ from drug dosing?

Accepted Answer

Phage numbers can increase at the infection site as they replicate on the target population, then fall once the host bacteria are cleared, producing a curve unlike any small molecule. Dose-response can be non-monotonic, and immune clearance shortens exposure. Measuring titre in tissue over time is more informative than assuming standard dosing behaviour.

Biotechnology

Biotechnology

Research Frontiers in Bacterial Phage Therapy Development